Important note to Members of the Cancer Center
Please remember to acknowledge NCI support in your publications.
The USC Norris Comprehensive Cancer Center (NCCC) has a long tradition of providing innovative and cost-effective Shared Resources (SRs) to advance high impact basic, translational, clinical, and population science research. Under the leadership of Joseph Wiemels, PhD, the USC Norris Administration ensures continuous improvement in SRs through a variety of rigorous planning and evaluation mechanisms. In response to robust planning and evaluation processes, we have six USC Norris SRs, including: 1) Flow Cytometry and Immune Monitoring SR, 2) Liquid Biopsy SR (formerly Circulating Tumor Cells), 3) Molecular Genomics SR, 4)Translational Pathology SR, 5) Data Science SR (formerly Biostatistics, and renamed to reflect the expansion to include bioinformatics), and 6) a new Population Research SR created in response to member feedback, especially from population scientists. To learn more, click below.
Provides advanced flow cytometry, cell sorting and immune monitoring capabilities and services for advancing basic and translational research.
Is a state-of-the-art, multi-platform facility for capture and analysis of peripheral blood CTCs and matched plasma nucleic acids, available to USC Norris members
Provides services for industry-standard and state-of-the-art molecular and genomic assays in support of USC Norris investigators working across the continuum of basic, translational, clinical and population sciences
Provides high-quality tissue procurement, processing, and banking resources to USC Norris investigators working on all aspects of cancer research.
Provides integrated state-of-the-art biostatistics and informatics support USC Norris investigators working on all aspects of cancer research from basic science to translational and clinical studies, and cancer etiology to cancer control.
Provides members with consultation and coordinated access to unique local and national population-based data resources and assessment tools.
Provides consultation and support for the use of preclinical models, including patient-derived xenografts, intending to generate data to foster the development of novel drug compounds or combinations for the treatment of cancer.